Skip to content
10-Q

Quarterly Report

CytomX Therapeutics, Inc. CTMX

0000950170-25-068511

← back to feed
Filed
May 12, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · Apr 30, 2025 80.62M sh
Cash And Equivalents Q1 2025 · Mar 31, 2025 $47.6M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $38.05M
Current Liabilities Q1 2025 · Mar 31, 2025 $50.2M
Current Liabilities Q1 2025 · Dec 31, 2024 $85.77M
Total Liabilities Q1 2025 · Mar 31, 2025 $73.45M
Total Liabilities Q1 2025 · Dec 31, 2024 $120.99M
Current Assets Q1 2025 · Mar 31, 2025 $86.63M
Current Assets Q1 2025 · Dec 31, 2024 $107.31M
Total Assets Q1 2025 · Mar 31, 2025 $98.5M
Total Assets Q1 2025 · Dec 31, 2024 $120.53M
Shares Diluted Q1 2025 · Mar 31, 2024 82.63M sh
Capex Q1 2025 · Mar 31, 2024 $115K
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$26.05M
Stockholders Equity Q1 2025 · Mar 31, 2024 −$31.68M
Stockholders Equity Q1 2025 · Dec 31, 2023 −$47.45M
Sga Expense Q1 2025 · Mar 31, 2024 $7.75M
Rd Expense Q1 2025 · Mar 31, 2024 $22.05M
Net Income Q1 2025 · Mar 31, 2024 $13.79M
Operating Income Q1 2025 · Mar 31, 2024 $11.66M
Revenue Q1 2025 · Mar 31, 2024 $41.46M